Polypharmacy in individuals with ASD was estimated between 5.4% and 54%. 22 Likewise, a recent systematic review reported that the rate of psychotropic With ID have been reported between 11% and 60%, depending on the study design and 22, 25, 26 Polypharmacy is frequent in these populations, and rates among individuals 24 Furthermore, polypharmacy and excessive dosages are common inĬhildren/adolescents and adults with ASD/ID. 13 – 21 Notably, psychotropic medication use increases with age 22, 23 and is highest in individuals with both ASD and ID. With ASD/ID have been reported in many countries. High rates of use of psychotropic medications for children/adolescents and adults Psychiatric disorders than other individuals approximately 30% of individuals with ID 10 and 70% with ASD have comorbid psychiatric disorders. 7 – 9 In addition, individuals with ASD/ID have higher rates of comorbid 5, 6 Such challenging behaviors often persist into adulthood. Present with problem behaviors including aggression toward others, self-injuriousīehavior, and disruptive behavior. 4 Children/adolescents with ASD and/or ID (i.e., ASD/ID for short) often It is estimated that 1% to 2% of the population are affected by either intellectualĭisability (ID) or autism spectrum disorder (ASD), 1 – 3 which are neurodevelopmental disorders according to the fifth edition of theĭiagnostic and Statistical Manual of Mental Disorders. ParmiĬelles-ci, sept et cinq études examinaient l’impact des polymorphismesĪboutissant surtout à des résultats d’étude négatifs. L’hyperprolactinémie chez les patients traités par rispéridone. En ce quiĬoncerne les effets secondaires, neuf études sur 15 portaient sur Études, dont trois rapportaient des associations significatives. Réponse au traitement par antidépresseurs qui a été investiguée dans quatre Par rispéridone 2) le polymorphisme SLC6A4 5-HTTLPR et la Études, dont deux rapportaient une association avec la réponse au traitement (rs6280) était examiné chez les patients traités par rispéridone dans trois ![]() Traitement étaient rapportés pour deux ensembles d’études de gènesĬandidats, notamment: 1) le polymorphisme DRD3 Ser9Gly Les résultats les plus intéressants pour la réponse au Incluaient des patients traités par antipsychotiques et antidépresseurs, Principalement la réponse au traitement, parmi lesquelles cinq et six études ![]() Les 25 autres études se concentraient spécifiquement sur lesĮnfants/adolescents souffrant de TSA/DI. Seulement trois études incluaient des adultes souffrant de TSA/DI alors que Un total de 28 études PGx recourant surtout à des approches de gènesĬandidats ont été identifiées dans tous les groupes d’âge. Among them, 7Īnd 5 studies examined the impact of CYP2D6 andĭRD2 Taq1A polymorphisms, respectively, yielding mostly On hyperprolactinemia in patients treated with risperidone. In regard to side effects, 9 of 15 studies focused SLC6A4 5-HTTLPR polymorphism and treatment response toĪntidepressants which was investigated in 4 studies, 3 of which reported Patients treated with risperidone in 3 studies, 2 of which reported anĪssociation with risperidone treatment response and (2) the The DRD3 Ser9Gly (rs6280) polymorphism was examined in Most interesting resultsįor response were reported for 2 sets of candidate gene studies, namely: (1) ![]() Treatment response, of which 5 and 6 studies included patients treated withĪntipsychotics and antidepressants, respectively. Notably, only 3 studies included adults withĪSD/ID while the other 25 studies focused specifically onĬhildren/adolescents with ASD/ID. A total of 28 PGx studies using mostly candidate gene approaches were
0 Comments
Leave a Reply. |